This is BMInsider PRO content
You're reading a Deep Dive — our most in-depth research. Unlock full access to all analyses, Smart Money breakdowns & more.
Unlock BMInsider PRO →One-time payment · instant access · no account needed
In the summer of 2024, Novo Nordisk was the most valuable company in Europe. Two years later, roughly a quarter of its $640 billion market value remains. The genuinely unsettling part is not the size of the fall — it is what happened at the same time to the market the company sells into: it grew faster than anyone had promised. That combination makes this the most expensive and most instructive case study of the decade.
Anyone who bought into obesity drugs in 2023 was buying a story about a market going from nothing to well over a hundred billion dollars. That story turned out to be right — the forecasts were actually raised again in 2026. And yet one of the two leaders lost three quarters of its value while the other became a trillion-dollar company. This analysis takes apart why that is not a contradiction but the norm, and what every investor should carry away from it into the next growth story they are pitched.
The forecasts went up, not down
Start with the number that most directly contradicts the popular narrative. If Novo Nordisk's collapse were the consequence of a disappointing market, the sell-side estimates would have been slashed by now. The opposite happened. In June 2026 Goldman Sachs raised its forecast for the global weight-loss drug market from $101 billion to roughly $114 billion by 2030 — explicitly citing faster uptake of oral drugs, stronger demand outside the United States and improved affordability. Morgan Stanley lifted its 2030 estimate from $77 billion to $105 billion and sees a peak of about $150 billion in 2035. J.P. Morgan puts the entire incretin market at $200 billion by 2030.
The total addressable market, in other words, delivered. The patients are there, the drugs work, demand still outstrips supply in many countries. And yet an investor who bought Novo Nordisk at the June 2024 high is sitting on a loss of roughly three quarters. An investor who bought Eli Lilly instead owns a security now valued above a trillion dollars.
When the same correct forecast produces two opposite outcomes, the forecast was never the real investment question. The real question was: who in this value chain has the power to set the price — and for how long?
Anatomy of a collapse
The decline did not happen in a day. It came as a chain of disappointments, each of which looked survivable on its own.
| When | Event | Effect |
|---|---|---|
| June 2024 | All-time high, market cap around $640bn | Europe's most valuable company |
| Dec. 2024 | First CagriSema data below expectations | doubts about the next-generation molecule |
| 2025 | New CEO, restructuring: 9,000 jobs (11% of staff) | DKK 8bn annual cost savings targeted |
| Feb. 2026 | Guidance: first-ever sales decline (–5% to –13%) | shares roughly 18% lower in a day |
| Feb. 2026 | CagriSema misses non-inferiority vs. tirzepatide | shares more than 16% lower |
| May 2026 | Q1: guidance nudged up to –4% to –12% | first stabilization, driven by the Wegovy pill |
The February 2026 double blow is the one to study. First management had to concede that 2026 would bring the first revenue decline in the company's modern history — in a market growing at double digits. Weeks later CagriSema, the combination of semaglutide and cagrilintide, missed its endpoint in the head-to-head trial: 23 percent weight loss at 84 weeks sounds impressive, but it was not enough to establish statistical non-inferiority against tirzepatide. With that, the hope of reclaiming technological leadership evaporated.
Mike Doustdar took over as chief executive in the summer of 2025 and responded with cost cuts: 9,000 positions and roughly 8 billion Danish kroner of annual savings. Cost cuts are a reasonable answer to a margin problem. They are not an answer to a competitive one.
The market-share tipping point
Market share tells the story more precisely than any price chart. Across the combined GLP-1 market in diabetes and obesity, Eli Lilly now holds roughly 60.1 percent against Novo Nordisk's 39.4 percent. More striking still: in May 2026 Lilly overtook its Danish rival outside the United States as well — in the territory long considered Novo's home advantage, with entrenched distribution and decades of diabetes relationships.
The quarterly numbers say the same thing in absolute terms. Eli Lilly grew first-quarter 2026 revenue 56 percent to $19.8 billion; Mounjaro rose 125 percent worldwide to $8.7 billion and U.S. Zepbound 79 percent to $4.1 billion. Full-year guidance was raised to $82–85 billion. Novo Nordisk posted DKK 96.8 billion in the same quarter and still had to guide to a full-year decline.
It would be wrong, though, to read this as a death spiral. The Wegovy pill, launched in the U.S. on January 5, 2026, beat expectations decisively: about DKK 2.26 billion of first-quarter revenue against a consensus of DKK 1.16 billion, more than two million prescriptions since launch, and 65 percent of all new U.S. prescriptions going to the Wegovy brand. That is precisely why Novo could nudge guidance higher in May. The company has not disappeared — it has gone from monopolist to strong number two. For shareholders, the difference between those two states was worth roughly $480 billion.
Why the molecule matters more than the marketing
In consumer markets, brand, distribution and price decide the winner. In pharmaceuticals, molecule quality decides first — and it does so brutally. Tirzepatide, the active ingredient behind Mounjaro and Zepbound, hits two receptors (GIP and GLP-1); semaglutide hits one. In head-to-head data that difference showed up consistently as greater weight loss. Physicians, payers and patients responded exactly as you would expect.
The general point for investors is this: in a market where products are objectively comparable — here in percent of body weight, measured in randomized trials — there is very little room for soft differentiation. A beverage company can paper over a taste disadvantage with brand spending. A pharmaceutical company cannot paper over an inferior trial curve. Investing in such markets means, at bottom, betting on a research pipeline, and pipelines carry far more uncertainty than a polished TAM slide implies.
The pill rewrites the economics
2026 opened the second front: oral dosing. Both companies now have a tablet on the market, but they are fundamentally different technologies — and that difference is central to future margins.
| Wegovy pill (Novo Nordisk) | Foundayo / orforglipron (Eli Lilly) | |
|---|---|---|
| Molecule class | oral peptide (semaglutide) | small molecule |
| U.S. launch | January 5, 2026 | approved April 1, 2026; shipping from April |
| Trial result | 16.6% weight loss at 64 weeks (full adherence) | more than 12% at the top dose (ATTAIN-1) |
| How it is taken | fasted, 30-minute wait before eating | any time of day, no food or water restriction |
| U.S. self-pay price | about $149 per month | from $149 per month, as low as $25 with some plans |
Peptides have to be produced by fermentation or complex synthesis, purified, and — in the injectable case — filled into pens. That fill-finish capacity was exactly the bottleneck that propped up prices in 2023 and 2024. A small molecule like orforglipron, by contrast, can be pressed in conventional tablet lines at essentially any volume. When a market loses its physical bottleneck, it loses its scarcity premium. That is not a pharmaceutical rule; it is an industrial one.
In the launch race Novo led at first: 18,000 prescriptions in the first full week versus 5,612 for Foundayo in its third. But that lead comes from an earlier start date, not a structural edge. And the decisive question was never who writes more scripts — it is at what price.
From scarcity pricing to discount pricing
Here is where the value was destroyed. Almost the entire profit pool of this market sat in the United States, where list prices above $1,000 a month were standard. Within twelve months that price architecture has been dismantled — partly by policy, partly by competition itself.
| Channel | Price per month | Effective |
|---|---|---|
| U.S. list price Wegovy / Ozempic / Rybelsus | $675 (a cut of up to 50%) | January 2027 |
| Medicare / Medicaid (negotiated) | $245 | January 2027 |
| Medicare copay, severe obesity | $50 | from mid-2026 |
| Government direct-to-consumer platform | about $350, stepping down toward $250 | since January 2026 |
| Manufacturer self-pay programs | $149 (as low as $25 with some plans) | 2026 |
| German pharmacy price (Wegovy) | €172 to €277 | already reality |
Read that table from the bottom up. A German self-payer has been paying between €172 and €277 a month for years. The American list price is now heading toward $675, and the manufacturer self-pay price is already at $149. What is happening is a convergence of U.S. pricing down toward European levels — and since the overwhelming majority of global profit came from the American price premium, that is not a footnote. It is half the investment thesis.
Policy adds to it. Semaglutide was pulled into Medicare price negotiation; the negotiated price is $245 and takes effect in January 2027. In parallel, agreements struck with both manufacturers in November 2025 trade price concessions for broader coverage, including a $50 copay pathway for severe obesity in Medicare from mid-2026. For the companies this is a classic swap: more volume for less margin per pack. Whether that swap supports profits or erodes them depends entirely on how much volume actually arrives — and how many competitors end up sharing it.
The forgotten map: where the patents have already fallen
One detail missing from most analyses is the geography of patent protection. Investors tend to think of patent expiry as a single date. It is in fact a map with very different dates, and a large part of that map is already open.
| Region | Semaglutide core patent expiry | Status |
|---|---|---|
| Canada | January 4, 2026 | first G7 country; immediate generic filings |
| India | March 2026 | multiple manufacturers launched within days |
| China | March 2026 | a queue of late-stage generic candidates |
| Europe | March 2031 (with supplementary certificate) | protected |
| United States | December 2031; formulation patents into 2032 | protected |
Canada, India, China, Brazil and Turkey together account for a very large share of the world's population — and there the molecule has been generic since this year. That guts precisely the narrative most often used to justify the growth case: expansion into populous emerging markets. Volume will come, in enormous quantities. It will simply be sold at generic prices, and the revenue will accrue to Indian and Chinese manufacturers.
The core U.S. market stays protected into late 2031, and Novo Nordisk has built a dense thicket of more than 300 patent filings around that window; estimates of U.S. revenue over the protected period run into the hundreds of billions. But the time value of that protection is shrinking. A patent with five years left is a completely different asset in a discounted cash flow model than one with twelve — and that transition is happening right now.
The second wave is already staged
Anyone who thinks the competitive picture is fully described by a duopoly is underestimating the pipeline. Amgen is running two large Phase 3 programs with MariTide, dosed monthly rather than weekly — a tangible convenience advantage. Pfizer picked up MET-097i through its acquisition of Metsera, also monthly and now in Phase 3. Roche holds several candidates via the Carmot acquisition and its Zealand Pharma partnership, with a Phase 3 decision on petrelintide due this year.
For future pricing, this may be the single most important fact in this analysis. A two-player market can sustain fat margins for years — think of aircraft manufacturing or card networks. A field of five or six well-capitalized entrants whose products are measured on the same metric moves almost inevitably toward price competition. The question is no longer whether this market reaches $114 billion. It is how many tills that money passes through, and how much of it survives as profit.
What is priced in? Valuation and scenarios
Two extremes now face each other. Novo Nordisk trades on a price-to-earnings ratio of roughly 11 — about half its own ten-year median of nearly 24. Eli Lilly trades at more than three times that: around 32 on forward earnings and above 40 on trailing, at a market value near a trillion dollars.
Both valuations embed a heavy assumption. Novo's price assumes earnings shrink durably. Lilly's price assumes leadership converts into steadily rising profits across the coming decade, despite price pressure and pipeline competition. One stock is cheap because almost nobody expects recovery; the other is expensive because almost everybody expects continuation. Historically, those two positions have rarely both been right at the same time.
| Scenario | Assumption | Novo Nordisk | Eli Lilly |
|---|---|---|---|
| Price war | Orals drive price down; five suppliers from 2028 | margins stay under pressure; valuation justified | growth persists, multiple compresses sharply |
| Base case | Volume offsets price; duopoly holds through the decade | stabilization, return to moderate growth | earnings grow into the valuation |
| Indication expansion | Reimbursed for heart, kidney, sleep apnea, liver | re-rating plausible; the cheaper option on this outcome | further upside, but dearly paid for |
The third scenario deserves particular attention because it is the strongest refutation of the bear case. If these drugs establish themselves beyond weight loss as standard therapy in cardiovascular, renal or liver disease, they change category: from expensive lifestyle treatment to reimbursable standard of care. Reimbursement raises volume dramatically and simultaneously makes price less decisive, because the health system pays rather than the patient. Investors who consider that outcome likely will find the more asymmetric bet in Novo Nordisk's current valuation.
The real lesson: the TAM trap
The case generalizes, and that is where its lasting value lies. A big addressable-market slide is the most comfortable argument in capital markets, because it is emotionally persuasive and almost impossible to falsify. But it answers only the first of three necessary questions.
The second question is: how much of that market drops through as profit — and to whom? Aviation is the textbook example. Passenger volumes multiplied over decades while shareholders in the industry collectively earned close to nothing. The same holds for solar, where installed capacity exploded while module prices and manufacturer share prices collapsed together. And for the PC industry of the 1990s, where the volume sat with the assemblers and the profit with two suppliers.
The third question is: how long is that profit protected? A patent is a clock running backwards from day one. An advantage built on manufacturing capacity lasts until competitors finish building. An advantage built on a better molecule lasts until the next trial reads out. In obesity drugs all three protections came under pressure simultaneously — and that, not a weak market, explains the missing $480 billion.
Practically: whenever a growth story opens with a market-size slide, skip the slide and test three things — the structure of competition, the source of pricing power, and its expiry date. Applied to obesity drugs in 2024, that test would have produced the same answers the market delivered to itself, painfully, in 2026.
Access, tax and the coverage question for U.S. investors
Access is straightforward for U.S. investors, with one wrinkle worth knowing. Eli Lilly is an ordinary domestic holding. Novo Nordisk is most easily held through its U.S.-listed shares, and Denmark withholds 27 percent on dividends at source. The U.S.–Denmark treaty caps the rate at 15 percent, but the difference has to be reclaimed from the Danish tax authority — a process that takes months and is rarely worth the effort on small positions. Holding the Danish name inside a tax-deferred account is generally the worse choice for exactly this reason: foreign withholding cannot be offset with the foreign tax credit inside an IRA, so the withheld amount is simply lost.
The more consequential question for U.S. investors is not tax but coverage, because coverage decides the addressable volume. Employer plans spent 2025 and 2026 tightening obesity-drug benefits, adding prior authorization or dropping coverage outright as costs mounted. Against that, the November 2025 agreements with the administration open a Medicare pathway for severe obesity at a $50 copay from mid-2026 and set a $245 negotiated price from January 2027. The direction of travel is clear: broader access at materially lower realized prices. For a volume business that is good news; for a margin business it is not, and these companies have been valued as margin businesses.
The compounding and telehealth channel is the wild card. When branded supply was short, compounded semaglutide filled the gap at a fraction of the price and trained a large cohort of patients to expect low cash prices. Manufacturer self-pay programs at $149 a month are, in part, a response to that anchor. Once patients have been anchored at that level, moving them back up is extremely hard — which is why the $149 number, not the $675 list price, is the one to watch in future disclosures.
One more contrast is worth carrying: Germany, the largest European market, does not reimburse these drugs for weight loss at all. Its statutory insurers classify them as lifestyle medication, explicitly excluded by law, a position the courts upheld in 2025. Patients there pay €172 to €277 a month out of pocket. That is a preview of a demand curve set by household willingness to pay rather than by insurance — and it is a useful sanity check on any model that assumes European volumes at American margins.
Bottom line
The obesity drug market delivered everything it was credited with in 2023. Forecasts went up, the drugs work, demand is real. And buying the then-market leader was still one of the worst decisions available in this cycle. The reason lies not in the market but in its structure: a better competing molecule, a disappearing production bottleneck, politically enforced price cuts, a patent map already open across the most populous countries, and a second wave of well-funded competitors.
So the question to ask about this sector today is not how big the market will be in 2030. That question has been answered and it is no longer the decisive one. The question is who, in 2030, will still get to decide what a month's supply costs. Eli Lilly's price today assumes it will be Eli Lilly. Novo Nordisk's price assumes it will be nobody. The real investment decision lives in the space between those two assumptions.